(Albany, US) DelveInsight added a new report titled Chronic Lower Back Pain (CLBP) Market Insights, Epidemiology and Market Forecast–2032 to its portfolio.
DelveInsight’s ‘Chronic Lower Back Pain Market Insights, Epidemiology and Market Forecast–2032‘ report proffers an in-depth understanding of Chronic Lower Back Pain, its etiology, and manifestations, a detailed analysis of the disease historical as well as forecasted epidemiology trends, its prevalence, incidence and patient pool. The report covers the comprehensive layout of the available marketed or approved therapies for CLBP and the upcoming therapies in the pipeline in the Chronic Lower Back Pain market with unmet needs, market drivers and barriers that may impact the growth of the market size in the next decade in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Moreover, the Chronic Lower Back Pain Market Insights report lays in front the therapy that has the potential to occupy the significant chunk of the CLBP market, competitors’ analysis, key collaborations, licensing opportunities, R&D scenario and influential non-profit organizations working for CLBP patients’ relief.
Some key facts of Chronic Lower Back Pain Market:
- Chronic Lower Back Pain Market landscape involves 15+ companies actively working in advancing CLBP market.
- Of the emerging therapies, Braeburn Pharmaceuticals/Camurus, Pfizer/Eli Lilly and Company, Mesoblast, Egalet Corporation are expected to launch their respective products, during the forecast period.
- Supportive treatment regimens entirely dominate the current CLBP market size along with the drugs that have been approved to treat comorbidities associated with CLBP, and those that are approved for chronic pain usually.
- The current opioid prescription market is expected to decline in the coming years because CLBP patients will switch from currently prescribed opioids to emerging opioid therapies, such as Buprenorphine and Egalet‐002.
- Limited Chronic Lower Back Pain treatment options are the major market driving forces in the CLBP market.
Request a sample page: https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market
Lower back pain is a common ailment, and at everyone at a certain point of time must have felt it. However, if the pain persists for more than 3-months, it is referred to as chronic lower back pain and is the second leading cause of the disability and degraded quality of life worldwide. The origin, as well as the intensity of the pain, may vary from an injury, disease to stress and from mild to severe.
Chronic Lower Back Pain Epidemiology
According to DelveInsight’s analysis, the total CLBP prevalent population in the 7MM was observed to be ~75,000000 in 2019, which is expected to increase during the study period, i.e., 2019–2032. A higher percentage of diagnosed prevalence was observed for females in comparison to males, in all the 7MM countries, except Japan, wherein males occupy a larger patient pool than females. Also, it has been observed that CLBP is mostly diagnosed in the age group of 40–69.
Present therapies in the CLBP market only provide temporary relief from the pain. At present, the Chronic Lower Back Pain market is dominated by opioids. However, the long-term opioid use results in addiction; hence the current scenario demands products with better safety profile and improved Quality of Life (QoL).
The report offers exhaustive coverage of the marketed as well as the emerging drugs.
Chronic Lower Back Pain Marketed Drugs
- Cymbalta: Eli Lilly and Company
- Xtampa: Collegium Pharmaceutical
- Butrans: Purdue Pharma
- Belbuca: BioDelivery Sciences International
- And many others
Request a sample page: https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market
Chronic Lower Back Pain Drugs in Pipeline:
- Tanezumab: Eli Lilly/Pfizer
- Fasinumab: Regeneron Pharmaceuticals/ Teva Pharmaceuticals
- MPC-06-ID: Mesoblast
- Egalet‐002 (Egalet Corporation)
- AXS‐02 (Axsome Therapeutics)
- ALLOD‐2 (Allodynic Therapeutics)
- ASP7962 (Astellas Pharma)
- CAM2038 (Braeburn Pharmaceuticals/Camurus)
- Clonidine Micropellets (Sollis Therapeutics)
- NKTR‐181 (Nektar Therapeutics)
- GRT6005: Grünenthal GmbH
- AB001: Frontier Biotechnologies
- IDCT (DiscGenics)
- YH14618 (Yuhan Corporation)
- SP‐102 (Semnur Pharmaceuticals)
- SX600 (SpineThera)
- And many others
Have a look at the sample report: https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market
Scope of the Chronic Lower Back Pain Market Report
- Geography Covered: The United States, EU5 (Germany, Spain, Italy, France, and The United Kingdom), and Japan
- Study Period: 3-year historical and 11-year forecasted analysis (2019-2032)
- Epidemiology Segmentation: Gender-Specific, Age-Specific, Severity Specific, Total diagnosed etc.
- Markets Segmentation: By Geographies, By therapies
- Companies Covered: Braeburn Pharmaceuticals, Camurus, Regeneron Pharmaceuticals, Teva Pharmaceutical, Pfizer, Eli Lilly and Company, Mesoblast, Egalet Corporation, Axsome Therapeutics, Allodynic Therapeutics, Astellas Pharma, Grünenthal GmbH, Frontier Biotechnologies, DiscGenics, Yuhan Corporation, Semnur Pharmaceuticals, Sollis Therapeutics, SpineThera, Stayble Therapeutics, AnGes MG, Asahi Kasei Pharma, and others.
- Comparative Analysis: Comparative and conjoint analysis of emerging therapies.
- Case Studies
- KOL’s Views
Request a WebEx walkthrough of the report: https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market
Reason to purchase
- Bespoke primary and secondary research
- 24*7 post-sale customer support
- Option for customizing and personalizing research reports as per needs
Table of Contents
|
1 |
Key Insights |
|
2 |
Chronic Lower Back Pain (CLBP) Market Overview at a Glance |
|
3 |
Executive Summary |
|
4 |
SWOT Analysis |
|
5 |
Chronic Lower Back Pain – Disease Background and Overview |
|
6 |
Chronic Lower Back Pain Epidemiology Methodology |
|
7 |
Chronic Lower Back Pain Epidemiology and Patient Population |
|
8 |
United States-specific Chronic Lower Back Pain Epidemiology |
|
9 |
Japan-specific Chronic Lower Back Pain Epidemiology |
|
10 |
Chronic Lower Back Pain Treatment Algorithm, Current Treatment, and Medical Practices |
|
11 |
Proposed Guidelines for Chronic Lower Back Pain |
|
12 |
Unmet Needs in Chronic Lower Back Pain Market |
|
13 |
Chronic Lower Back Pain Marketed Products |
|
14 |
Chronic Lower Back Pain Emerging Therapies |
|
15 |
Chronic Lower Back Pain Market Forecast Methodology |
|
16 |
Chronic Lower Back Pain – 7MM Market Analysis |
|
17 |
Conjoint Analysis |
|
18 |
United States: Chronic Lower Back Pain Market Outlook |
|
19 |
EU-5 countries: Chronic Lower Back Pain Market Outlook |
|
20 |
Japan: Chronic Lower Back Pain Market Outlook |
|
21 |
Case Reports |
|
22 |
Chronic Lower Back Pain Market Drivers |
|
23 |
Chronic Lower Back Pain Market Barriers |
|
24 |
Appendix |
|
25 |
DelveInsight Capabilities |
|
26 |
Disclaimer |
About Delveinsight:
DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting